MGX:NASDAQMetagenomi Therapeutics, Inc. analysis
Data as of Oct 14, 2026 - not real-time
- Latest price
- $0.92
- Risk: high
- 9/10High risk
Summary
Metagenomi Therapeutics, Inc. is priced at $0.9200 and its moving averages line up in bearish order, the shorter trailing the longer. Over a rolling month the price has lost 21.4%. Relative strength is 28.1 — oversold — and the MACD signal is bearish. Recent trading has carved out support near $0.8946 and resistance around $1.16.
The company is not currently profitable on a trailing basis, so earnings multiples offer no valuation support. Sell-side targets cluster 660.9% above the current quote.
On a 1-10 scale the risk profile lands at 9 — high. With 30-day volatility of 49.8%, a beta of 1.39 and a maximum drawdown of 72.6%, position sizing matters more than entry timing here. Thin trading volumes mean execution costs can be material on larger orders. The wider market backdrop reads extreme greed at 93 on the fear-greed composite.
Across every horizon the signals point the same way: hold, at a conviction of 1 out of 10.
The company is not currently profitable on a trailing basis, so earnings multiples offer no valuation support. Sell-side targets cluster 660.9% above the current quote.
On a 1-10 scale the risk profile lands at 9 — high. With 30-day volatility of 49.8%, a beta of 1.39 and a maximum drawdown of 72.6%, position sizing matters more than entry timing here. Thin trading volumes mean execution costs can be material on larger orders. The wider market backdrop reads extreme greed at 93 on the fear-greed composite.
Across every horizon the signals point the same way: hold, at a conviction of 1 out of 10.
Top market events
- Metagenomi Therapeutics MGX delivered earnings and revenue surprises of -15.
- EMERYVILLE, Calif., Sept. 01, 2026 GLOBE NEWSWIRE -- Metagenomi Therapeutics, Inc. Nasdaq: MGX the “Company” , an...
- MarketScreener1dMetagenomi Therapeutics, Inc.
Market outlook
Short term
< 1 yearNeutral
Model confidence3/103 out of 10
Key factors
- Short-term moving averages stacked below long-term ones
- RSI at 28.1 signals oversold conditions
- Trading below the 200-day average of 1.35
Medium term
1–3 yearsNeutral
Model confidence2/102 out of 10
Key factors
- Short-term moving averages stacked below long-term ones
- RSI at 28.1 signals oversold conditions
- Trading below the 200-day average of 1.35
Long term
> 3 yearsNeutral
Model confidence1/101 out of 10
Key factors
- Analyst targets imply +660.9% versus the current price
- Negative return on equity of -60.6%
- Negative free cash flow
Key metrics
Financial health
P/E Ratio-0.5
ROE-60.61%
ROA-28.19%
Debt/Equity33.51
P/B Ratio0.3
Op. Cash Flow$-85487000
Free Cash Flow$-50950752
Industry P/E30.7
Technical analysis
TrendBearish
RSI28.1
Support$0.89
Resistance$1.16
MA 20$1.06
MA 50$1.14
MA 200$1.35
MACDBearish
VolumeIncreasing
Fear & Greed Index93.36
Valuation
Target Price$7.00
Upside/Downside660.87%
GradeUndervalued
TypeBlend
Risk assessment
Beta1.39
Volatility49.83%
Sector RiskMedium
Reg. RiskHigh
Geo RiskLow
Currency RiskLow
Liquidity RiskHigh
Similar tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.